



# 10  
COPY OF PAPERS  
ORIGINALLY FILED

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 29 2002

TECH CENTER 1600/2900

Applicant(s): Volkens, et al.

Examiner: TBA

Serial No.: 10/005,371

Group Art Unit: 1655

Filed: December 5, 2001

Docket No.: 570-21 CPA/CON

For: APPLICATIONS WITH AND  
METHODS FOR PRODUCING  
SELECTED INTERSTRAND CROSS-  
LINKS IN NUCLEIC ACIDS

Date: August 19, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

*I hereby certify this correspondence is being deposited  
with the United States Postal Service as first class mail,  
postpaid in an envelope, addressed to:  
Assistant Commissioner for Patents, Washington, D.C.  
20231 on August 19, 2002  
Dated: 08/19/02*

AMENDMENT

Sir:

This amendment to the above-identified application is being filed in response to the "Notice of Incomplete Reply" mailed on July 26, 2002. As required by the Notice, paper and computer readable copies of the Sequence Listing accompany this Amendment. Entry of this Amendment is respectfully requested.

IN THE SPECIFICATION:

On page 32, please replace the paragraph beginning on line 14 with the following:

In this example the experiments described in example 2 were essentially repeated. Human Papillomavirus (HPV) type 16 primers HPVfor (SEQ ID NO.: 1) and HPVrev (SEQ ID NO.: 2) yielded a fragment of 945 bp in a polymerase chain reaction (PCR). Four internal primers were designed: primer TU16for1 (SEQ ID NO.: 3), primer TU16for2 (SEQ ID NO.: 4), primer TU16rev1 (SEQ ID NO.: 5), and primer TU16rev2 (SEQ ID NO.: 6). These internal primers were pooled (0.125  $\mu$ g/ $\mu$ l each). The primer mixture was labelled with 50 ng trans-ULS per  $\mu$ g primers according to the standard ULS labelling protocol. Next, the oligonucleotide mix was column purified in order to remove free trans-ULS. Total genomic